Fatty Liver Disease, Overweight
Conditions
Brief summary
To assess whether orange peel fermentation has the effect of reducing body fat in adults
Detailed description
This is a double-blind and randomized study. Subjects are informed to consume the samples every day for 2 months. The clinical diagnosis item of overweight or fatty liver is evaluated by the doctor. The questionnaires are collected at every visit of the trial.
Interventions
DIETARY_SUPPLEMENTPlacebo
consume 1 sachet per day for 2 months
DIETARY_SUPPLEMENTorange peel fermentation
consume 1 sachet per day for 2 months
Sponsors
TCI Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject. 2. For those with BMI ≥ 24 or fatty liver, male body fat ≥ 25%, female body fat ≥ 30%. 3. Those who are not pregnant and are willing to cooperate with contraception during the trial period. 4. No history of cardiovascular disease, history of organ transplantation, history of epilepsy or convulsions, liver and kidney disease, malignant tumor, endocrine disease, mental disease, alcohol or drug abuse, or other major organic diseases (according to medical history).
Exclusion criteria
1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history). 2. No person who has received major surgery or bariatric surgery (according to medical history). 3. I have used drugs that affect body fat, waist circumference or significantly increase weight, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability in the current or 3 months before participating in the screening Drugs (according to medical history).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change of body fat mass | Weeks 0, 4 and 8 | The body fat mass (kg) was assessed by InBody770 |
| The change of Triglyceride | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of Triglyceride |
| The change of Total cholestrol | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of Total cholestrol |
| The change of HDL-cholestrol | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of HDL-cholestrol |
| The change of LDL-cholestrol | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of LDL-cholestrol |
| The change of body mass index (BMI) | Weeks 0, 4 and 8 | BMI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass.The body mass index (BMI, kg/m\^2) and body mass (kg) were assessed by InBody770. |
| The change of body fat percentage | Weeks 0, 4 and 8 | The body fat percentage (%) was assessed by InBody770. |
| The change of visceral fat | Weeks 0, 4 and 8 | The visceral fat (10 cm\^2) was assessed by InBody770. |
| The change of fasting glycemia | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of fasting glycemia |
| The change of aspartate aminotransferase | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of aspartate aminotransferase |
| The change of alanine aminotransferase | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of alanine aminotransferase |
| The change of albumin | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of creatine |
| The change of creatine | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of creatine |
| The change of uric acid | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of uric acid |
| The change of white blood cell | Weeks 0, 4 and 8 | Venous blood was sampled to measure concentrations of white blood cell |
Countries
Taiwan
Contacts
CONTACTHUANG YU-JYUN
PRINCIPAL_INVESTIGATORLIOU JYH-MING, Doctor
National Taiwan University Hospital
Outcome results
None listed